Esteri Chetonici per il Trattamento dello Scompenso Cardiaco Acuto (KETO-AHF)
KETO-AHF: Esteri Chetonici per il Trattamento dell'Insufficienza Cardiaca Acuta: Uno Studio Controllato Randomizzato di Avanguardia
Ketones have been suggested to have significant physiological effects in patients with heart failure. Potential mechanisms for these effects include energy provision for the failing heart and direct protective effects on other organs. Despite the strong physiological rationale, the acute effects of ketone therapy in patients with acute heart failure (AHF) is unclear. AHF is a major healthcare issue, with in-hospital mortality exceeding 10%. Therefore, we propose a vanguard randomized controlled trial to assess the effects of ketone esters in patients with AHF. Sixty patients hospitalized with AHF will be randomized to receive either 25 grams of ketone esters three times per day or a matching placebo for five days, or until death or hospital discharge. We hypothesize that ketone therapy will improve markers of systemic congestion and heart failure symptoms. Primary endpoint will be changes in NT-proBNP levels during therapy. Secondary endpoints will be KCCQ scores, and hemodynamic profile as assessed by echocardiogram. Exploratory endpoints will clinical outcomes including mortality, need for intensive care unit admission, among others.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
KETO-AHF (Ketone Ester for Treatment of Acute Heart Failure) is a single-site, double-blind, randomized, placebo-controlled vanguard clinical trial evaluating the feasibility, safety, and preliminary efficacy of exogenous ketone ester therapy in adults hospitalized with acute heart failure (AHF). The trial is conducted as a domain within the Heart Failure Efficacy and Research Trial (HEART) Platform master protocol framework.
Adults (≥18 years) admitted with a primary diagnosis of acute heart failure will be screened and enrolled within 48 hours of hospital admission. Eligible participants must have dyspnea and clinical evidence of congestion and meet protocol-specified laboratory and clinical criteria, including elevated NT-proBNP and adequate kidney function (eGFR >15 mL/min/1.73m²). Key exclusions include type 1 diabetes mellitus, dialysis dependence, inability to tolerate enteral therapy, and need for advanced mechanical circulatory support or inopressor therapy.
Participants will be randomized 1:1 to receive ketone ester therapy or matching placebo for up to 5 consecutive days (or until hospital discharge or death), in addition to standard-of-care acute heart failure management. Randomization will occur through a centralized web-based system using stratified randomization by sex, and both participants and study staff will remain blinded to allocation.
The investigational intervention is KetoneAid MonoEster (D-β-hydroxybutyrate bonded to R-1,3-butanediol), administered orally or enterally at 25 g three times daily (total 75 g/day). The placebo arm receives a taste- and appearance-matched placebo administered on the same schedule. Study drug administration occurs after meals with flexibility to accommodate clinical care.
The primary endpoint is change in NT-proBNP over the treatment period. Secondary outcomes include change in heart failure symptoms using the Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score and change in echocardiographic measures of cardiac function. Exploratory outcomes include glycemic control and insulin requirements, renal function, daily fluid balance adjusted for diuretic dose, and clinical outcomes through 30 days including mortality and days alive and out of hospital. The vanguard design also evaluates feasibility outcomes to inform a subsequent full-scale trial, including consent rate, representation of women, intervention adherence, and follow-up completeness.
Safety monitoring includes daily clinical assessment and laboratory monitoring (including acid-base measures), with predefined adverse events of special interest and stopping rules. An independent Data Safety Monitoring Committee (DSMC) reviews safety data at prespecified enrollment intervals.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Justin Ezekowitz, MD
- Numero di telefono: 780-492-0712
- Email: jae2@ualberta.ca
Backup dei contatti dello studio
- Nome: Fernando G Zampieri, MD, PhD
- Numero di telefono: 587-588-6151
- Email: fzampier@ualberta.ca
Luoghi di studio
-
-
Alberta
-
Edmonton, Alberta, Canada
- University of Alberta
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Domain-Specific Inclusion Criteria:
- Primary diagnosis of AHF with dyspnea on exertion or at rest, and at least two of the following: congestion on chest radiograph, rales on chest auscultation, clinically relevant edema, or an elevated jugular venous pressure [21]
- Admitted to the hospital for less than 48 hours
- Estimated glomerular filtration rate above 15 mL/min/1.73m²
- NT-proBNP ≥ 1000 pg/ml
Domain-Specific Exclusion Criteria:
- Type 1 diabetes mellitus
- Patients on mechanical circulatory support
- Patients on more than one inotrope or on inopressors
- Patients on dialysis
- Patients with non-functioning enteral tracks
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: KetoneAid MonoEster
Intervention Name: KetoneAid MonoEster Formulation: D-Beta Hydroxybutyrate bonded to R 1,3 Butanediol Dosing: 25 grams, three times per day Administration: Oral or enteral route Duration: 5 consecutive days, or until hospital discharge or death |
Participants randomized to the intervention arm will receive KetoneAid MonoEster (D-β-hydroxybutyrate bonded to R-1,3-butanediol) administered orally or enterally at a dose of 25 g three times daily (total 75 g/day) for up to 5 consecutive days (or until discharge or death), in addition to standard of care acute heart failure management. |
|
Comparatore placebo: Placebo
Matching placebo, also provided by KetoneAid, with similar administration instructions. |
Participants randomized to the control arm will receive a matching placebo administered orally or enterally three times daily for up to 5 consecutive days (or until discharge or death), in addition to standard of care acute heart failure management. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in NT-proBNP
Lasso di tempo: Baseline to Day 5 (or hospital discharge if earlier)
|
Change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) level over the 5-day intervention period comparing ketone ester versus placebo. |
Baseline to Day 5 (or hospital discharge if earlier)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS)
Lasso di tempo: Baseline to Day 5 (or hospital discharge if earlier)
|
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score from baseline to Day 5 comparing treatment groups. The Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) ranges from 0 to 100, where higher scores indicate fewer heart failure symptoms and better health status, and lower scores indicate more severe symptoms and worse health status. |
Baseline to Day 5 (or hospital discharge if earlier)
|
|
Change in Left Ventricular Ejection Fraction (LVEF)
Lasso di tempo: Baseline to Day 5 (or hospital discharge if earlier)
|
Change in left ventricular ejection fraction from baseline to Day 5 comparing ketone ester versus placebo. Left ventricular ejection fraction is expressed as a percentage (%), with higher values indicating better systolic function. |
Baseline to Day 5 (or hospital discharge if earlier)
|
|
Change in Mitral Inflow E/e' Ratio
Lasso di tempo: Baseline to Day 5 (or hospital discharge if earlier)
|
Change in mitral inflow E/e' ratio from baseline to Day 5 comparing ketone ester versus placebo. E/e' ratio is a unitless measure of left ventricular filling pressure. Higher values indicate higher estimated filling pressures and worse diastolic function. |
Baseline to Day 5 (or hospital discharge if earlier)
|
|
Change in Stroke Volume
Lasso di tempo: Baseline to Day 5 (or hospital discharge if earlier)
|
Change in stroke volume from baseline to Day 5 comparing ketone ester versus placebo. Stroke volume is measured in milliliters (mL). Higher values indicate greater forward blood flow per heartbeat. |
Baseline to Day 5 (or hospital discharge if earlier)
|
|
Change in Tricuspid Annular Plane Systolic Excursion (TAPSE)
Lasso di tempo: Baseline to Day 5 (or hospital discharge if earlier)
|
Change in tricuspid annular plane systolic excursion from baseline to Day 5 comparing ketone ester versus placebo. TAPSE is measured in millimeters (mm). Higher values indicate better right ventricular systolic function. |
Baseline to Day 5 (or hospital discharge if earlier)
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in serum creatinine
Lasso di tempo: Baseline to Day 5 (or discharge if earlier)
|
Change in renal function measured by serum creatinine over the intervention period. |
Baseline to Day 5 (or discharge if earlier)
|
|
Insulin requirements
Lasso di tempo: Day 1 through Day 5 (or discharge if earlier)
|
Total insulin administered during the inpatient intervention period. |
Day 1 through Day 5 (or discharge if earlier)
|
|
Glycemic control
Lasso di tempo: Day 1 through Day 5 (or discharge if earlier)
|
Daily blood glucose measurements during the intervention period. |
Day 1 through Day 5 (or discharge if earlier)
|
|
Days Alive and Out of Hospital
Lasso di tempo: 30 days
|
Number of days alive and out of hospital through Day 30 after randomization. |
30 days
|
|
All-cause mortality
Lasso di tempo: 30 days
|
All-cause mortality through Day 30 after randomization. |
30 days
|
|
Major Adverse Kidney Events
Lasso di tempo: 30 days
|
Composite kidney outcome through Day 30, including death, new renal replacement therapy, or persistent renal dysfunction. |
30 days
|
|
Daily Net Fluid Balance Adjusted for Loop Diuretic Dose
Lasso di tempo: Day 1 through Day 5 (or hospital discharge if earlier)
|
Daily net fluid balance during the inpatient intervention period (Day 1 through Day 5 or hospital discharge if earlier), adjusted for total loop diuretic dose administered. Net fluid balance will be calculated as total fluid intake minus total fluid output and normalized to loop diuretic dose received during the same period. |
Day 1 through Day 5 (or hospital discharge if earlier)
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Fernando G Zampieri, MD, PhD, University of Alberta
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- KETO-01
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .